About MKI67 FHA domain-interacting nucleolar phosphoprotein
MKI67 FHA domain-interacting nucleolar phosphoprotein (NIFK) is a protein
from Homo sapiens identified by UniProt accession
Q9BYG3, 293 residues long.
MolForge cross-references it against 0 known binders and
119 disease associations.
Target properties
| Protein name | MKI67 FHA domain-interacting nucleolar phosphoprotein |
|---|
| UniProt accession | Q9BYG3 |
|---|
| Gene | NIFK |
|---|
| Organism | Homo sapiens |
|---|
| Length | 293 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (119)
Diseases linked to this target (Open Targets).
- heart failure · score 0.43
- obese body mass index status · score 0.30
- overweight body mass index status · score 0.30
- hypertension · score 0.25
- smoking status measurement · score 0.19
- irritability measurement · score 0.19
- Irritability · score 0.18
- central nervous system disease · score 0.09
- retinal vein occlusion · score 0.09
- hepatocellular carcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BYG3-F1 | alphafold | PREDICTED | 72.88 | — |
Amino-acid sequence (293 residues)
MATFSGPAGP ILSLNPQEDV EFQKEVAQVR KRITQRKKQE QLTPGVVYVR HLPNLLDETQ IFSYFSQFGT VTRFRLSRSK RTGNSKGYAF VEFESEDVAK IVAETMNNYL FGERLLECHF MPPEKVHKEL FKDWNIPFKQ PSYPSVKRYN RNRTLTQKLR MEERFKKKER LLRKKLAKKG IDYDFPSLIL QKTESISKTN RQTSTKGQVL RKKKKKVSGT LDTPEKTVDS QGPTPVCTPT FLERRKSQVA ELNDDDKDDE IVFKQPISCV KEEIQETQTP THSRKKRRRS SNQ
Explore MKI67 FHA domain-interacting nucleolar phosphoprotein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets